These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 21128888)

  • 1. Therapeutic antibodies in HIV treatment--classical approaches to novel advances.
    Abela IA; Reynell L; Trkola A
    Curr Pharm Des; 2010; 16(33):3754-66. PubMed ID: 21128888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and In Vivo Characterization of Immunoconjugates Targeting HIV gp160.
    Pincus SH; Song K; Maresh GA; Frank A; Worthylake D; Chung HK; Polacino P; Hamer DH; Coyne CP; Rosenblum MG; Marks JW; Chen G; Weiss D; Ghetie V; Vitetta ES; Robinson JE; Hu SL
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27795412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of Current Cell-Penetrating Antibody Developments for HIV-1 Therapy.
    Che Nordin MA; Teow SY
    Molecules; 2018 Feb; 23(2):. PubMed ID: 29415435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro efficacy of anti-HIV immunotoxins targeted by various antibodies to the envelope protein.
    Pincus SH; Cole RL; Hersh EM; Lake D; Masuho Y; Durda PJ; McClure J
    J Immunol; 1991 Jun; 146(12):4315-24. PubMed ID: 1710247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Human Anti-HIV gp160 Monoclonal Antibodies That Make Effective Immunotoxins.
    Pincus SH; Song K; Maresh GA; Hamer DH; Dimitrov DS; Chen W; Zhang MY; Ghetie VF; Chan-Hui PY; Robinson JE; Vitetta ES
    J Virol; 2017 Feb; 91(3):. PubMed ID: 27852851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo efficacy of anti-glycoprotein 41, but not anti-glycoprotein 120, immunotoxins in a mouse model of HIV infection.
    Pincus SH; Fang H; Wilkinson RA; Marcotte TK; Robinson JE; Olson WC
    J Immunol; 2003 Feb; 170(4):2236-41. PubMed ID: 12574398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Curr Pharm Des; 2000 Feb; 6(3):261-76. PubMed ID: 10637379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broadly neutralizing antiviral antibodies.
    Corti D; Lanzavecchia A
    Annu Rev Immunol; 2013; 31():705-42. PubMed ID: 23330954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection.
    Bruno CJ; Jacobson JM
    J Antimicrob Chemother; 2010 Sep; 65(9):1839-41. PubMed ID: 20639524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting strategies for delivery of anti-HIV drugs.
    Ramana LN; Anand AR; Sethuraman S; Krishnan UM
    J Control Release; 2014 Oct; 192():271-83. PubMed ID: 25119469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new class of antigen-specific killer cells.
    Yang AG; Chen SY
    Nat Biotechnol; 1997 Jan; 15(1):46-51. PubMed ID: 9035105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific killing of HIV-infected lymphocytes by a recombinant immunotoxin directed against the HIV-1 envelope glycoprotein.
    Bera TK; Kennedy PE; Berger EA; Barbas CF; Pastan I
    Mol Med; 1998 Jun; 4(6):384-91. PubMed ID: 10780881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of HIV by chemokine receptor antagonists: exciting new targets, complex development.
    Henson GW
    Expert Rev Anti Infect Ther; 2003 Oct; 1(3):347-9. PubMed ID: 15482129
    [No Abstract]   [Full Text] [Related]  

  • 14. Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life.
    Boesch AW; Alter G; Ackerman ME
    Curr Opin HIV AIDS; 2015 May; 10(3):160-9. PubMed ID: 25700208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A modified SCID mouse model of HIV infection with utility for testing anti-HIV therapies.
    Pincus SH; Fang H; Wilkinson RA; Olson WC; Marcotte TK
    AIDS Res Hum Retroviruses; 2003 Oct; 19(10):901-8. PubMed ID: 14585222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of CXCR4 in HIV infection and its potential as a therapeutic target.
    Murakami T; Yamamoto N
    Future Microbiol; 2010 Jul; 5(7):1025-39. PubMed ID: 20632803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection.
    Bekker V; Scherpbier H; Pajkrt D; Jurriaans S; Zaaijer H; Kuijpers TW
    Pediatrics; 2006 Aug; 118(2):e315-22. PubMed ID: 16847077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of broadly neutralizing antibodies for HIV-1 prevention.
    Pegu A; Hessell AJ; Mascola JR; Haigwood NL
    Immunol Rev; 2017 Jan; 275(1):296-312. PubMed ID: 28133803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.